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Chagas disease, caused by the protozoan parasite Trypanosoma cruzi (T. cruzi), is characterized by immunopathology driven by
IFN-𝛾 secretingTh1-like T cells. T. cruzi has a thick coat of mucin-like glycoproteins covering its surface, which plays an important
role in parasite invasion and host immunomodulation. It has been extensively described that T. cruzi or its products—like GPI
anchors isolated from GPI-anchored mucins from the trypomastigote life cycle stage (tGPI-mucins)—are potent inducers of
proinflammatory responses (i.e., cytokines and NO production) by IFN-𝛾 primed murine macrophages. However, little is known
about whether T. cruzi or GPI-mucins exert a similar action in human cells. We therefore decided to further investigate the in vitro
cytokine production profile from human mononuclear cells from uninfected donors exposed to T. cruzi as well as tGPI-mucins.
We observed that both living T. cruzi trypomastigotes and tGPI-mucins are potent inducers of IL-12 by human peripheral blood
monocytes and this effect depends onCD40-CD40L interaction and IFN-𝛾. Our findings suggest that the polarizedT1-type cytokine
profile seen in T. cruzi infected patients might be a long-term effect of IL-12 production induced by lifelong exposure to T. cruzi
tGPI-mucins.
1. Introduction
The protozoan parasite Trypanosoma cruzi is the causative
agent of Chagas disease, which affects approximately 15 mil-
lion people in South andCentral America [1, 2]. It is estimated
that about 30% of infected individuals will develop severe
chronic forms of the disease, especially the often fatal Chagas
disease cardiomyopathy (CCC) [1–4]. Intracellular protozoan
parasites are potent stimulators of innate and cell-mediated
immunity. The induction of macrophage proinflammatory
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cytokines by ligands of innate immunity receptors of T.
cruzi is considered important in the control of infection
and outcome of Chagas disease [5, 6]. It has been exten-
sively described that glycosylphosphatidylinositol-anchored
mucins-like glycoproteins from Trypanosoma cruzi trypo-
mastigotes (tGPI-mucins) activate murine macrophages in
vitro to produce the proinflammatory cytokines tumor necro-
sis factor 𝛼 (TNF-𝛼) and interleukin- (IL-) 12 as well as nitric
oxide (NO) [7, 8]. The bulk of evidence establishes that IL-12
and IL-12 drivenTh1 cytokines, the ones involved in delayed-
type hypersensitivity, are induced during acute infection
with T. cruzi in mice, playing an obligatory role in parasite
clearance and host survival [9–12]. T. cruzi tGPI-mucins
were shown to initiate the inflammatory response through
an activation of Toll-like receptors TLR2 [7, 13]. Different
components from this parasite are capable of activating TLRs
in dendritic cells and macrophages, like the unmethylated
CpG motifs present in T. cruzi genome, were identified as
a TLR9 agonist [14]. T. cruzi chronically infected Chagas
disease patients display a Th1 cytokine profile [15] which is
even more pronounced among CCC patients [16, 17]. It has
been described that certain infectious agents, like Mycobac-
terium tuberculosis, possess molecules stimulating innate
immunity that can shift the systemic cytokine environment
and modify clinical immune profiles [18]. Our group and
others have previously reported that heart-infiltrating T cells
predominantly produce IFN-𝛾 and TNF-𝛼, suggesting that
suchTh1 T cells play an important pathogenetic role in heart
tissue damage in CCC [16, 19–22]. Even though acute T. cruzi
infection induces IL-12 production in mice, little is known
about whether T. cruzi or tGPI-mucins exert a similar action
in humans. We have previously described the isolation of
live T. cruzi trypomastigotes outgrowing from a heart biopsy
fragment from a CCC patient [23], routinely cultured for the
study of outgrowing heart-infiltrating T cells [16, 24]. In order
to study whether T. cruzi and tGPI-mucins could directly
induce the production of the Th1-inducing cytokine IL-12
in human cells, we studied the cytokine profile in naturally
infected supernatants of heart-infiltrating mononuclear cells.
We also assessed the effect of cocultivation of T. cruzi and
tGPI-mucins with peripheral blood mononuclear cells and
purified monocytes on IL-12 production. Finally, we assessed
the role of IFN-𝛾 and CD40L signaling on T. cruzi and tGPI
mucin-induced IL-12 production.
2. Methods
2.1. Parasites. The Y strain of T. cruzi was maintained in
fibroblast cultures and was used as parasite source for purifi-
cation of tGPI-mucins. For the trypomastigote culture, L-929
fibroblasts were initially infected with blood trypomastigotes
in a ratio of one parasite per cell. The tissue culture try-
pomastigotes were continuously passed in L-929 fibroblast
cultures.The infected cultures weremaintained in Dulbecco’s
modified Eagle’s medium (DMEM) containing 5% fetal calf
serum (FCS) at 33∘C in 5% CO
2
. After 4 or 5 days of culture,
the parasites were collected daily and centrifuged at 40 g at
4∘C for 10min for cellular debris separation, followed by
another centrifugation at 700 g at 4∘C for 10min. The result-
ing pellet containing live trypomastigotes was used to purify
GPI-mucins.
2.2. Purification of tGPI-Mucins. The GPI-mucins were iso-
lated from T. cruzi trypomastigotes as described previ-
ously [7, 8] using sequential organic extraction followed
by hydrophobic-interaction chromatography in an Octyl-
Sepharose column (Amersham Pharmacia Biotech, Uppsala,
Sweden) and elution with a propan-1-ol gradient (5–60%).
2.3. Heart-Infiltrating T Cell Lines. T cell lines were estab-
lished from endomyocardial biopsy explants from CCC
patients as described [16]. Briefly, biopsy tissue was minced
and seeded on to 96-well flat bottom plates in the pres-
ence of IL-2 and irradiated peripheral blood mononuclear
cells (PBMC) until lymphoblast outgrowth was observed; T
cell lines were expanded by restimulation every two weeks
with 5 𝜇g phytohemagglutinin (PHA) and irradiated PBMC.
PBMC were obtained from blood of healthy donors and
separated by density gradient centrifugation with Ficoll-
Hypaque𝑅. All cells were cultured in Dulbecco’s modified
Eagle’smedium supplementedwith 2mML-glutamine, 1mM
sodium pyruvate, MEM’s nonessential amino acids and
MEM’s vitamins (all from GIBCO, Grand Island, NY, USA),
50 𝜇g/mL gentamicin, 10mMHEPES buffer, and 10% normal
human serum (complete medium). This protocol has been
approved by the Institutional Review Board of the University
of Sa˜o Paulo School of Medicine and all subjects provided
informed consent.
2.4. T. cruzi Coculture/GPI Treatment. Ten to 12 days after
the last PHA stimulation, heart-infiltrating T cell lines (from
four different individuals, in separate experiments) were
stimulated in the presence of irradiated PBMC (5 × 105/well)
plus 5𝜇g/mL PHA and supernatants were obtained after
48 h incubation. In another set of experiments, culture
conditions included variable components: irradiated PBMC,
heart-infiltrating T cell lines (from four different individu-
als), 5 𝜇g/mL PHA, 5 × 104 Y strain T. cruzi trypomastig-
otes obtained from LLC-MK2 monolayer cell culture, or
10 pmol/mL of T. cruzi tGPI-mucins. Blocking/neutralizing
monoclonal antibodies against CD28, CD40, and IFN-𝛾
(Pharmingen, La Jolla, CA) were employed in selected exper-
iments.
2.5. Human Monocytes. Human monocytes were obtained
by leukapheresis of normal volunteers at the blood bank of
National Institutes of Health (Bethesda, MD). After density
sedimentation of the mononuclear cells with lymphocyte
separation medium (Organon, Teknika, Durham, NC), the
monocytes were purified by counterflow centrifugal elutria-
tion, as described previously [25], except that pyrogen-free
PBS was used in the elutriation procedure. Monocytes were
enriched >90% as determined by morphology, non-specific
esterase staining, and flow cytometry.The purification proce-
dure did not activate themonocytes, as shown by the fact that,
after overnight incubation at 37∘C in suspension, 4% of
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Figure 1: T. cruzi trypomastigotes outgrowth from endomyocardial biopsies from CCC patients induces the production of T1-type cytokine
profile.
the cells were IL-12R positive or spontaneously secreted any
of the cytokines measured. After purification, monocytes
were left at 4∘C overnight and then transferred to 5mL
polystyrene Falcon tubes (Becton Dickson Labware, Lincoln
Park, NJ) and cultured for 24 h in the presence or absence
of 10 pmol/mL tGPI-mucins, in the presence or absence
of 100 units/mL of human IFN-𝛾 (Genetech), as indicated.
Culture supernatants were collected 48 h after stimulation for
IL-12 determination.
2.6. CytokineMeasurements. Cytokines IFN-𝛾, IL-4, IL-2, IL-
10, IL-12, and TNF-𝛼 were measured by double sandwich
ELISA using the anti-human cytokine antibody pairs (R&D
Systems, Minneapolis).
3. Statistical Analysis
Groups were compared by a nonparametrical test (Mann-
Whitney Rank Sum Test) with GraphPad InStat software
(version 5.0; GraphPad). Results were expressed as medians
and interquartile ranges. 𝑃 values were considered significant
if <0.05.
4. Results
4.1. T. cruzi Outgrowth from Endomyocardial Biopsies from
CCC Patients Induces the Production of T1-Type Cytokine Pro-
file. We routinely cultured T cell lines from endomyocardial
biopsies from CCC patients for the isolation of T cell lines.
In one of these biopsy explants, highly motile T. cruzi trypo-
mastigotes were observed in some of the seeded wells, indi-
cating that the tissue fragments in those wells probably con-
tained a T. cruzi pseudocyst. We therefore compared PHA-
stimulated cytokine production in the supernatant from the
T cell line established from wells containing live T. cruzi
parasites (with T. cruzi trypomastigote growth) with the cell
line derived from wells of the same biopsy devoid of T. cruzi
(no T. cruzi trypomastigote growth). Figures 1(a) and 1(b)
depict the cytokine profile of the T cell line obtained from
the T. cruzi-positive wells as compared to the T cell line
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Figure 2: T. cruzi-induced IL-12 production is potentiated by
activated T cells. Results come from 4 distinct experiments. Groups
were compared by a nonparametrical test (Mann-Whitney Rank
Sum Test) with GraphPad InStat software (version 5.0; GraphPad).
Results were expressed asmedians and interquartile ranges.𝑃 values
were considered significant if <0.05.
of the same sample, obtained from wells where no T. cruzi
trypomastigotes were observed. As can be seen, T. cruzi
trypomastigotes outgrowth induced the production of IL-
12, TNF-𝛼, and IFN-𝛾, with undetectable levels of IL4. The
presence of T. cruzi strongly reduced the levels of IL-2 and
mildly reduced IL-10 levels.
4.2. T. cruzi Trypomastigotes Induce IL-12 Production by
Human PBMC, Which Is Potentiated by Activated T Cells. To
further investigate the phenomenon observed in the endomy-
ocardial biopsies wells we assayed cytokine production in
supernatants of human PBMC in the presence of living T.
cruzi and/or PHA-activated T cells. As shown in Figure 2, T.
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Figure 3: tGPI-mucins from T. cruzi induce IL-12 production
by human monocytes. Results come from 3 distinct experiments.
Groups were compared by a nonparametrical test (Mann-Whitney
Rank Sum Test) with GraphPad InStat software (version 5.0; Graph-
Pad). Results were expressed as medians and interquartile ranges. 𝑃
values were considered significant if <0.05.
cruzi trypomastigotes can inducemoderate production of IL-
12 directly on irradiated PBMC or in cocultures of PBMC and
T cells. However, coculture with PHA-activated T cell lines
induced a 10- to 100-fold increase in IL-12 production by
irradiated PBMC.
4.3. GPI-Mucins from T. cruzi Trypomastigotes Induce IL-12
Production by Human Monocytes. We also tested if purified
tGPI-mucins could activate isolated PBMC-derived mono-
cytes in vitro to produce IL-12. As shown in Figure 3, tGPI-
mucins induce significant production of IL-12 by human
monocytes, which is further potentiated after IFN𝛾 priming
of cells.
4.4. Induction of IL-12 Production by T. cruzi or tGPI-Mucins
Is Dependent on IFN-𝛾 and CD40-CD40L Interactions. In an
attempt to study themechanisms underlyingT. cruzi-induced
potentiation of IL-12 production by human monocytes, we
cocultured these cells with PHA-activated T cell lines, 5 ×
104 T. cruzi Y strain living trypomastigotes, or tGPI-mucins
and added neutralizing/blocking antibodies to human IFN-
𝛾, CD40, and CD28. Results indicated that blocking IFN-𝛾
or CD40 individually caused approximately 50% and 35%
of inhibition of IL-12 production, respectively, while anti-
CD28 showed negligible inhibition. The combined effect of
the three antibodies induced 85% of inhibition, suggesting
that most of the IL-12-inducing effects of PHA-activated T
cell lines are due to IFN-𝛾 production and CD40-CD40L
interactions (Figure 4(a)). Similar results were obtainedwhen
tGPI mucin was used as stimulus (Figure 4(b)) suggesting
that these molecules may be the effectors in the T. cruzi-
induced IL-12 production in humans, as has been previously
described in mice [8].
5. Discussion
In this paper, we observed that both living trypomastigotes
and tGPI-mucins are potent inducers of IL-12 production in
human monocytes and that this effect depends on CD40-
CD40L interaction and IFN-𝛾 signaling. The finding that
spontaneous outgrowth of parasites in culture cells derived
from chronically infected myocardium induced the produc-
tion of T1-type proinflammatory cytokines, like IL-12, TNF𝛼,
and IFN𝛾, is in accordance with data from murine models
from other studies [26–30]. These cytokines, which are
induced during acute infection with T. cruzi in mice, play an
obligatory role in parasite clearance andhost survival [26, 29].
However, the same immunological pattern may participate
in mechanisms of tissue damage in Chagas disease, indicat-
ing that protective and pathological responses must share
important characteristics in this context [31]. When parasites
were deliberately added to cocultures of irradiated PBMCand
activated T cell lines, we observed again high levels of IL-
12 expression in PBMC, although the T. cruzi stimulus itself
was capable of inducing some IL-12 expression by PBMC
in the absence of activated T cells. This corroborates the
findings obtained with cultures with spontaneous outgrowth
of T. cruzi trypomastigotes, where we had PHA-activated cell
lines and T. cruzi trypomastigotes. Our results indicate that
PBMC-derivedmonocytes are the cell population responding
to tGPI-mucins with in vitro IL-12 production. Although we
already observed induction of IL-12 production by mono-
cytes using tGPI-mucins as a first signal (microbial stimulus
via TLR-2), maximal levels of IL-12 are reached only after a
second signal through the presence of IFN-𝛾, as it has been
reported by other studies [32, 33]. The alkylacylglycerolipid
component of tGPI-mucins [7] is capable of triggering
Toll-like receptors-2 at subnanomolar concentrations [13].
Moreover, macrophages derived from Tlr2−/− or Myd88−/−
mice are less responsive to tGPI-mucins, further confirming
the possible role of the TLR pathway in this process [34].
Our findings that anti-IFN-𝛾 and anti-CD40L neutralizing
antibodies were able to significantly reduce IL-12 production
indicate this phenomenon is mediated by IFN-𝛾 and CD40-
CD40L interactions.This can be explained by the fact that, in
this context, T cells are likely to be the major source of IFN-𝛾
and membrane CD40L, activators of macrophages involved
in many aspects of parasite control [11, 35]. As previously
described by Chaussabel et al. CD40 ligation in T. cruzi-
infected mice has a protective effect because it is related to
upregulation of IL-12 as well as NO by a direct stimulation
of INF-𝛾 activated macrophages [36]. Previous studies also
showed that the CD40-CD40L signaling pathway mediated
protective effect with other pathogens such as Leishmania
[37], Schistosoma mansoni [38], Cryptococcus neoformans
[39], Cryptosporidium parvum [40], and Pneumocystis carinii
[41]. The enhanced production of IFN-𝛾, TNF-𝛼, and nitric
oxide associated with CD40/CD40L signaling is thought to
be responsible for this protective effect. It was shown that
IFN𝛾 stimulus also upregulates the transcription factor T-bet
[42], which in turn maintains IL-12R𝛽 chain expression [43],
possibly resulting in a positive feedback loop that, conse-
quently, keeps the shift towards a Th1 response in Chagas
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Figure 4: Potentiation of IL-12 production induced by (a) live T. cruzi trypomastigotes or (b) tGPI-mucins is dependent on IFN-𝛾 and CD40.
Irradiated PBMCwere incubated with T cell lines, PHA (5 ug/mL), and different blocking antibodies (anti-IFN-𝛾, anti-CD40, anti-CD28, and
anti-IFN/CD40/CD28). Results come from 4 distinct experiments. Groups were compared by a nonparametrical test (Mann-Whitney Rank
Sum Test) with GraphPad InStat software (version 5.0; GraphPad). Results were expressed as medians and interquartile ranges. 𝑃 values were
considered significant if <0.05. Significance bars are shown in comparison with trypo + PHA or tGPI-mucin + PHA.
disease. In summary, our data suggest that the T1-type
cytokine profile found in the peripheral blood and among
heart-infiltrating T cells is related to previous or ongoing
encounters with IL-12 generated as a response toT. cruziGPI-
anchored mucin-like glycoproteins.
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